drug · small molecule
cannabidiol 1
Phase 3updated 5mo agoby $CRDL Cardiol Therapeutics Inc.🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 82 investigational indications.
targets
Cannabinoid receptor 1
all catalysts(0)
nothing on the calendar yet
Trials studying cannabidiol 1
- phase2Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis
- phase2Study of Cannabidiol and Neuroimaging on Stress
- phase3CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
- phase4Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
- phase3Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
- phase2Unique Treatment of Oncology Pain in Advanced Cancer
- phase2Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis
- phase4A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
News(4)
- New Jazz cancer drug approval could drive blockbuster salesZiihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.biopharma_dive · 1mo ago
- Jazz to buy rare epilepsy drugmaker in potentially $1.3B dealActio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.biopharma_dive · 1mo ago
- Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipelineJazz Pharmaceuticals is reaching into its wallet once again, this time buying Actio Biosciences and an experimental therapy for KCNT1+ epilepsy, a form of the disease with no FDA-approved treatments.biospace · 1mo ago
- Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapiesJazz Pharmaceuticals is adding to its orchestra of epilepsy treatments with the acquisition of Actio Biosciences for $820 million upfront.fiercebiotech · 1mo ago
Data sources
last refreshed 44m ago
Found something off?
comments(0)
5-min edit window · permanent after that